Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Terumo To Start U.S. Stent Trials

This article was originally published in PharmAsia News

Executive Summary

Major Japanese medical device maker Terumo will start clinical trials for Misago, a peripheral self-expanding stent indicated for femoral and popliteal artery disease in the U.S and Japan within the year. The company launched the product in Europe aiming for ¥10 billion in annual sales. Last year, Terumo opened a Swiss location for the launch of Nobori, a new generation of drug-eluting stent used in patients suffering from coronary artery disease, and Misago. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts